RenovoRx (RNXT) Competitors

RenovoRx (NASDAQ:RNXT) and MacroGenics (NASDAQ:MGNX) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, community ranking, risk, institutional ownership, profitability, valuation, earnings, media sentiment and analyst recommendations.

Does the MarketBeat Community prefer RNXT or MGNX?

MacroGenics received 415 more outperform votes than RenovoRx when rated by MarketBeat users. Likewise, 62.10% of users gave MacroGenics an outperform vote while only 52.38% of users gave RenovoRx an outperform vote.

Company	Underperform	Outperform
RenovoRx	Outperform Votes 11 52.38%	Underperform Votes 10 47.62%
MacroGenics	Outperform Votes 426 62.10%	Underperform Votes 260 37.90%

Does the media favor RNXT or MGNX?

In the previous week, RenovoRx had 1 more articles in the media than MacroGenics. MarketBeat recorded 4 mentions for RenovoRx and 3 mentions for MacroGenics. MacroGenics' average media sentiment score of 0.80 beat RenovoRx's score of 0.57 indicating that MacroGenics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
RenovoRx	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
MacroGenics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has stronger valuation & earnings, RNXT or MGNX?

MacroGenics has higher revenue and earnings than RenovoRx. RenovoRx is trading at a lower price-to-earnings ratio than MacroGenics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
RenovoRx	$43K	858.43	-$10.23M	-$0.39	-2.59
MacroGenics	$148.34M	0.76	-$9.06M	-$1.08	-1.66

Do analysts prefer RNXT or MGNX?

RenovoRx currently has a consensus price target of $6.00, suggesting a potential upside of 494.06%. MacroGenics has a consensus price target of $7.38, suggesting a potential upside of 312.01%. Given RenovoRx's stronger consensus rating and higher probable upside, equities analysts plainly believe RenovoRx is more favorable than MacroGenics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
RenovoRx	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00
MacroGenics	0 Sell rating(s)	8 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.36

Do insiders and institutionals hold more shares of RNXT or MGNX?

3.1% of RenovoRx shares are owned by institutional investors. Comparatively, 96.9% of MacroGenics shares are owned by institutional investors. 7.1% of RenovoRx shares are owned by company insiders. Comparatively, 11.3% of MacroGenics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Which has more risk and volatility, RNXT or MGNX?

RenovoRx has a beta of 1.12, suggesting that its share price is 12% more volatile than the S&P 500. Comparatively, MacroGenics has a beta of 2.23, suggesting that its share price is 123% more volatile than the S&P 500.

Is RNXT or MGNX more profitable?

RenovoRx has a net margin of 0.00% compared to MacroGenics' net margin of -69.07%. MacroGenics' return on equity of -89.42% beat RenovoRx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
RenovoRx	N/A	-205.96%	-110.01%
MacroGenics	-69.07%	-89.42%	-38.57%

Summary

MacroGenics beats RenovoRx on 12 of the 18 factors compared between the two stocks.